The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience

  • Park, Gun Ha (Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Lee, Chang Min (Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Song, Jae Won (Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Jung, Moon Chan (Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Jwa Kyung (Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Song, Young Rim (Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Hyung Jik (Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Sung Gyun (Department of Internal Medicine, Hallym University Sacred Heart Hospital)
  • Received : 2016.05.04
  • Accepted : 2016.07.08
  • Published : 2018.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Tolvaptan is a very effective treatment for hypervolemic or euvolemic hyponatremia. We compared the clinical efficacy of and response to tolvaptan in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and congestive heart failure (CHF). Methods: We retrospectively reviewed the medical records of 50 patients (SIADH, n = 30; CHF, n = 20) who were prescribed tolvaptan between July 2013 and October 2015. Tolvaptan was prescribed when the serum sodium level was < 125 mmol/L and the standard treatment failed. Normonatremia was defined as a serum sodium level of > 135 mmol/L. Results: After the initiation of tolvaptan therapy, there was an immediate response in the urine volume and serum sodium level in all patients. The improvements in the urine volume and serum sodium concentration were highest within the first 24 hours of treatment. In addition, the mean change in the serum sodium level during the first 24 hours was significantly higher in patients with SIADH than in those with CHF (${\Delta}Na$, $9.9{\pm}4.5mmol/L$ vs. $6.9{\pm}4.4mmol/L$, respectively; p = 0.025). Also, the mean maintenance dose was lower, and the total duration of tolvaptan use was slightly shorter in the SIADH group than CHF group ($21.5{\pm}14.9days$ vs. $28.0{\pm}20.1days$, p = 0.070). Conclusions: The early response to tolvaptan treatment was better in patients with SIADH than in those with CHF. Thus, the tolvaptan treatment strategy should be differed between patients with SIADH and those with CHF.

Keywords

References

  1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(7 Suppl 1):S30-S35. https://doi.org/10.1016/j.amjmed.2006.05.005
  2. Kim H, Lee H, Park HC, et al. Characteristics of severe hyponatremia in hospitalized patients: a comparison according to the presence of liver disease. Korean J Nephrol 2008;27:678-687.
  3. Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001;12 Suppl 17:S10-S14.
  4. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-S21. https://doi.org/10.1016/j.amjmed.2007.09.001
  5. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007;167:1998-2005. https://doi.org/10.1001/archinte.167.18.1998
  6. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122:857-865. https://doi.org/10.1016/j.amjmed.2009.01.027
  7. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin 2008;24:1601-1608. https://doi.org/10.1185/03007990802081675
  8. Peri A. Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 2013;98:1321-1332. https://doi.org/10.1210/jc.2012-4082
  9. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112. https://doi.org/10.1056/NEJMoa065181
  10. Nemerovski C, Hutchinson DJ. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Clin Ther 2010;32:1015-1032. https://doi.org/10.1016/j.clinthera.2010.06.015
  11. Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-732. https://doi.org/10.1530/EJE-10-1078
  12. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: association between non-responders and chronic kidney disease. Circ J 2013;77:397-404. https://doi.org/10.1253/circj.CJ-12-0971
  13. Narayen G, Mandal SN. Vasopressin receptor antagonists and their role in clinical medicine. Indian J Endocrinol Metab 2012;16:183-191. https://doi.org/10.4103/2230-8210.93734
  14. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-712. https://doi.org/10.1681/ASN.2009080857
  15. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-2460. https://doi.org/10.1161/01.CIR.0000165065.82609.3D
  16. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-1331. https://doi.org/10.1001/jama.297.12.1319
  17. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-2696. https://doi.org/10.1161/01.CIR.0000070422.41439.04
  18. Garcha AS, Khanna A. Review of tolvaptan in the treatment of hyponatremia. Clin Med Insights Ther 2011;3:315-325.
  19. Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-1211. https://doi.org/10.1016/S0002-9149(00)00729-3
  20. Shoaf SE, Ohzone Y, Ninomiya S, et al. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol 2011;51:761-769. https://doi.org/10.1177/0091270010376193

Cited by

  1. Update on heart failure management and future directions vol.34, pp.1, 2018, https://doi.org/10.3904/kjim.2018.428